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Editorial Neuromuscular relaxants-1997
T HE sixth International Neuromuscular Meeting was held in Paris in August. The original meeting, in London in 1975, was to act as a forum for investigators and industry (Burroughs Wellcome and Organon) in the hope that such a liaison would lead to the development of muscle relaxants needed by the clinician. In so far as the intermediate relaxants, atracttrium and vecuronium, were developed, the meetings can claim some success. The inaugural meeting is seldom counted as the first which was held in San Francisco in 1979 followed by Boston (1983), Los Angeles (1987), Montrtal (1992) and Tokyo (1994) . Strictly, the Paris meeting was the Seventh! In Paris, a combination of basic scientists, clinical pharmacologists and anaesthetists led to detailed discussion of many aspects of the pharmacological modification of signal transduction by the pentameric acetylcholine receptor at the neuromuscular junction. Three topics had particular relevance for clinicians.
Perhaps the most important was the presentation by J. Viby-Mogensen (Copenhagen, Denmark) of a controlled study examining the incidence of postoperative pulmonary complications (POPC) after the use ofpancuronium, atracurium or vecuronium during anaesthesia. 1 Pulmonary complications were defined as the combination of clinical signs and radiological evidence of atelectasis or infiltration occurring up to six days following surgery. (One of the authors, H. Berg, had previously received the Radiometer prize for original research after presentation of the paper at the Scandinavian Anaesthesia Society Congress in June). Although residual neuromuscular block, particularly after the use of long-acting relaxants, has been recognised for nearly 20 years, z no previous investigation has been able to demonstrate that this resulted in adverse effects. In this multicentre, prospective, study of 691 patients undergoing abdominal, gynaecological or major orthopaedic procedures and randomized for the choice of relaxant (pancuronium, vecuronium, atracurium), POPC occurred in 20 (8.7%) who had received pancuronium, 14 (6.1%) after vecuronium and 13 (5.6%) in the atracurium group. Multiple regression analysis demonstrated that abdominal surgery, age, and CAN J ANAESTH 1997 / 44:11 / pp 1135-1137 duration of surgery were general risk predictors. Pancuronium was a risk factor when combined with a train-of-four ratio of< 0.7 in the Recovery Room. The authors calculated that the risk of development of POPC in a 70-year-old man undergoing long-lasting abdominal surgery was about 45% in a patient who had received pancuronium and who was left with a TOF < 0.7 after surgery compared with 15% if either atracurium or vecuronittm had been used.
The message is clear. If long-acting muscle relaxants are used, it is essential to demonstrate that recovery has progressed to a TOF ratio > 0.7 at the end of surgery if an increased incidence of postoperative pulmonary complications is to be avoided. With this in mind, it is difficult to support the Duke University Clinical Guidelines suggesting that "succinylchollne and pancuronium are the default relaxants and should be considered for each procedure that requires muscle relaxation. "s Lubarsky et al., in Durham, North Carolina, should continue their studies into the postoperative period before claiming that such a policy does not induce adverse outcomes.
Dr. Marie-Claire Laxenaire (Nancy, France) gave an authoritative review of present knowledge of anaphylaxis during anaesthesia. Since 1984, muscle relaxants have been responsible for 60-80% of reported anaphylactic reactions during anaesthesia in France. 4 Whilst the incidence due to relaxants has decreased from 81% in 1984-9 to 62% in 1997, that due to latex has increased from 0.5 to 17%. Vecuronium was responsible for most (one third) of the reactions, in keeping with its major market share, and was followed by succinylcholine and atract~ium. However, the use of succinylcholine has decreased in France and now accounts for only about 5% of the use of relaxants. Nevertheless, it is responsible for 30% of the anaphylactic reactions.
Dr. Laxenaire suggested that all anaphylactic reactions should be investigated promptly. Initially, blood should be obtained within two hours to determine plasma histamine and trypsin concentrations, and to measure serum IgE against quaternary ammonium compounds. Four to six weeks later, skin testing (prick and intradermal) should be performed. A positive skin test must be followed by testing to all muscle relaxants as cross-sensitivity occurs in 75% of patients investigated.
No premedication (H l or H 2 blockade, steroids) can prevent anaphylactic shock from occurring. The only way to avoid such a reaction in a sensitive patient is to avoid the allergen causing the reaction -forever.
Surprisingly, only one new neuromuscular blocking agent, ORG 9487, was discussed in Paris. This experimental aminosteroid relaxant has low potency (EDgs ' 1 mg-kg-l), a rapid onset and short duration of action. Tracheal intubating conditions are good-excellent 60 sec after 1.5 mg.kg -I, and are followed by a clinical duration of about 15-20 min. With large or repeated doses, the recovery index gradually increases, probably a result of accumulation of the 3-OH metabolite that is cleared more slowly than the parent compound. There is some dispute whether early recovery can be induced by reversal with neostigmine given 2-5 rain after the relaxant. A previous study had suggested that when neostigmine was administered 5 rain after 1.3 mg-kg -~ ORG 9487, a TOF of 0.7 was reached within 10 min. s However, in Paris, (Liverpool, England) were unable to confirm this observation. 6 Early reversal would be a considerable advantage in situations when prompt recovery from a relaxant bolus were required. The combination of rapid onset and quick recovery, either spontaneous or assisted, would make the drug a potential candidate as a nondepolarizing succinylcholine replacement.
Mills et aL
In the current issue of the Canadian Journal of Anaesthesia, Schiere et aL compared equipotent doses ofvecuronium and ORG 9487 and showed, as expected, that ORG 9487 had a more rapid onset and shorter duration than vecuronium. Also, the duration of maintenance doses of ORG 9487 was shorter than those ofvecuronium whether preceded by ORG 9487 or by vecuronium. 7 It appears that ORG 9487 offers some advantages over currently available relaxants. However, the onset time is only slightly shorter than that of rocuronium. Further studies to confirm early reversibility, cardiovascular stability and behaviour under different conditions will be necessary before its introduction into clinical practice.
Les myorelaxants-1997
En aofit, avait lieu fi Paris le sixitme congrts international sur la transmission neuromusculaire. Radiometer de la recherche originale pour ce travail prfsentf au congr& de la Scandinavian Anaesthesia Society en juin) avaient dffini les complications pulmonaires postoptratoires comme une association de signes cliniques et radiologiques survenant dans les six jours suivant l'intervention. Bien que la curarisation rfsiduelle, surtout secondaire a l'administration de relaxants de longue dur& d'acfion, ait fit4 reconnue depuis au moins 20 ans, 2 aucune recherche ant&ieure n'avait rfussi ~ dfmontrer sa relation de cansalitf avec ces effets map heureux. Au cours de cette ftude multicentrique prospective de 691 patients soumis a une dfirurgie viscfrale, gyn&ologique ou orthopfdique majeure avec randomisation sur le choix des relaxants (pancuronium, v&uronium, atracurium), les auteurs ont observ6 des CPPO chez 10 (8,7%) de ceux qui avaient requ du pancuronium, chez 14 (6,1%), du v&uronium et 13 (5,6%), de l'atracufium. Une analyse de rfgression multiple a rfvtlf clue le site abdominal, Page du patient et la dur& de l'intervention consfituaient des prfdicteurs de risque gtnfraux. Lorsqu'associf a un rapport train-de-quatre (TOF) < 0,7 ~ la salle de rfveil, le pancuronium reprfsentait aussi un facteur de risque. Les auteurs ont calculf qu'un homme de 70 ans, soumis ~ une chirurgie viscfrale prolong& dont le rapport TOF &air inffrieur ~ 0,7 apt& l'intervention, encourait un risque de CPPO de 45% s'il avait requ du pancuronium comparativement ~ 15% s'il avait requ de l'atracurium ou du vfcuronium.
Le message est clair. Si on utilise des relaxants musculaires de longue dur& d'action, il est essentiel de confirmer que la r&upfration a progressf ~ un TOF > 0,7 ~ la fin de l'intervention si on veut fviter d'accroltre l'incidence des CPPO. Avec cette information, il est difficile d'appuyer la ligne de conduite proposfe par les directives de l'universit~ Duke selon lesquelles ~da succinylcholine et le pancuronium sont les relaxants de base et devraient &re consid~rfis pour toutes les interventions qui n&essitent un rel~chement musculaire,. 3 
I_x: Dr Marie-Claire Laxenaire (Nancy, France), tree autorit~ dans le domaine, a pr~sent~ une revue des connaissances actuelles sur l'anaphylaxie pendant l'anesth~sie g~n~rale. Depuis 1984, les relaxants musculaires ont 6t~ responsables de 60 ~ 80% des r6actions anaphylactiques rapport~es en France: Alors que l'incidence des rfiactions caus&s par les myorelaxants a diminu6 de 81% en 1984-9 ~ 62% en 1997, les r6actions au latex augmentaient de 0,5 ~ 17%. En proportion avec sa part importante du march6, le v&uronium &ait responsable de la plus grande partie (tin tiers) des rfiacfions, suivi de la succinylcholine et de l'atracurium. Cependant, en France. on utilise moins la succinylcholine qui ne repr~sente maintenant que 5% de tousles myorelaxants administrfis. N~anmoins, la succinylchofine demeure responsable de 30% de toutes les r~action anaphylactiques.
Le Dr l.axenaire propose d'explorer sans tarder route r6action anaphylactique. Au d~part, il faudrait prfilever du sang dans les deux heures pour le dosage des concentrations plasmatiques d'histamine et de trypsine et pour le titrage s&ique de l'IgE en presence de compos& ammonium tertiaire. Quatre ou six semaines plus tard, les ~preuves cutan&s (piqfire et intradermor6actrion) devraient suivre. Comme 75% des patients &udi~s sont sujets ~ une sensibilit~ crois&, tout test cutan6 positif devrait ~tre r~p&fi avec chacun des myorelaxants. Aucune pr6m~dication (inhibiteurs H~ et H 2, st~ro'fdes) ne peut pr&enir le choc anaphylactique. Pour les patients connus comme sensibles, la settle pr&ention efficace consiste &iter tout contact avec l'allerg~ne en cause et pour touiours.
A notre grande surprise, un seul nouveau relaxant musculaire a &6 pr6sent6 ~ Paris. II s'agit d'un aminost6roi'de experimental de faible puissance (EDgs 1 mg.kg -~) d'installation rapide et de courte dur6e d'action. Les conditions d'intubation sont de bonnes ~ excellentes 60 s apr~s l'administration de 1,5 mg-kg -1 et la curarisation ne dure que de 15 ~ 20 min. Avec des doses plus importantes ou r6p&&s, l'index de r&up~ration augmente graduellement, r6sultat probable de l'accumulation du m&abolite 3-OH dont l'61imination est plus lente que le produit original. Une r&up6ration pr&oce peut survenir si on administre de la n~ostigmine 2 ~ 5 min apr~s le relaxant: Une &ude ant~rieure avait en effet sugg&6 que lorsque la n6ostigmine &ait administr& 5 min awes 1,3 mg.kg -~ d'ORG 9487, le TOF remontait 0,7 en moins de 10 min. 6 Cependant, ~t Paris, Mills et aL (Liverpool, Angleterre) ont &6 incapables de confirmer cette observation: Une r6versibilit6 pr&oce pourrait procurer un avantage consid6rable dans les situations off la r&up&ation s'impose apr~s un simple bolus, s L'association installation et r&up6ration rapides, cette derni~re spontan& ou assist&, d6signe cet agent non d6polarisant comme candidat potentiel pour le remplacement de la succinylcholine.
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